rozanolixizumab   Click here for help

GtoPdb Ligand ID: 9801

Synonyms: CA170_01519.g57 IgG4P | rozanolixizumab-noli | Rystiggo® | UCB-7665 | UCB7665
Approved drug Immunopharmacology Ligand
rozanolixizumab is an approved drug (FDA (2023), EMA (2024))
Compound class: Antibody
Comment: Rozanolixizumab is an anti-human FcRn monoclonal antibody that is being developed for potential use in the treatment of IgG-driven autoimmune diseases [1,3-4].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Immunopharmacology Comments
In a first-in-human clinical trial rozanolixizumab produced sustained dose-dependent reductions in serum IgG concentrations [3].
Immunopharmacology Disease
Disease X-Refs Comment References
Myasthenia gravis Disease Ontology: DOID:437
OMIM: 254200
Orphanet: ORPHA589
 Phase 2 clinical candidate for myasthenia gravis- see NCT03052751
Autoimmune thrombocytopenic purpura Disease Ontology: DOID:8924
OMIM: 188030
Orphanet: ORPHA3002
 Phase 2 clinical candidate for primary immune thrombocytopenia- see NCT02718716